Results 1 to 10 of about 23,252 (167)
Development of a CYP2D6-enhanced HepaRG cell model with improved CYP2D6 metabolic capacity.
PLoS ONEDrug-induced liver injury is a major concern in drug development, and the limitations of animal models have driven interest in human-derived in vitro models for toxicity assessment.
Chizuka Obara +5 more
doaj +3 more sources
Frequency of CYP2D6*3 and *4 and metabolizer phenotypes in three mestizo Peruvian populations [PDF]
Pharmacia, 2021 Wild type genotypes (CYP2D6) and their allelic variants have been described in a sample of a Peruvian mestizo population. The global allele frequency was 0.015 for CYP2D6*3 and 0.051 for CYP2D6*4. The percentages of genotypes described were 97% CYP2D6*1/*
Angel T. Alvarado +10 more
doaj +3 more sources
In vitro study on the effect of peucedanol on the activity of cytochrome P450 enzymes
Pharmaceutical Biology, 2021 Context Peucedanol is a major extract of Peucedanum japonicum Thunb. (Apiaceae) roots, which is a commonly used herb in paediatrics. Its interaction with cytochrome P450 enzymes (CYP450s) would lead to adverse effects or even failure of therapy ...
Cun Zhang +4 more
doaj +1 more source
Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6 [PDF]
Xenobiotica, 2013 1. Metoclopramide is a widely used clinical drug in a variety of medical settings with rare acute dystonic events reported. The aim of this study was to assess a previous report of inactivation of CYP2D6 by metoclopramide, to determine the contribution of various CYPs to metoclopramide metabolism, and to identify the mono-oxygenated products of ...
Mara R, Livezey +5 more
openaire +2 more sources
Frontiers in Pharmacology, 2022 Aims: The CYP2D6*41 variant is the second or third frequent reduced function allele in Chinese with a frequency of around 3–4%, while it is the major reduced function allele in Indians, Saudi Arabians and Caucasians with frequencies of around 10–20%. The
Ye Jin +6 more
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2021 The cytochrome P450 (CYP) 2D6 enzyme exhibits large interindividual differences in metabolic activity. Patients are commonly assigned a CYP2D6 phenotype based on their CYP2D6 genotype, but there is a lack of consensus on how to translate genotypes into ...
Trine Frederiksen +4 more
doaj +1 more source
Does ethnicity impact CYP2D6 genotype–phenotype relationships?
Clinical and Translational Science, 2023 Polymorphism of the CYP2D6 gene leads to substantial interindividual variability in CYP2D6 enzyme activity. Despite improvements in prediction of CYP2D6 activity based on genotype information, large interindividual variability within CYP2D6 genotypes ...
Trine Frederiksen +4 more
doaj +1 more source
Development and validation of a next-generation sequencing panel for clinical pharmacogenetics [PDF]
Farmacia Hospitalaria, 2020 La rápida implantación clínica de las técnicas de secuenciación masiva en paralelo se debe a su capacidad para secuenciar un gran número de regiones genéticas con un coste menor a las técnicas convencionales.
Luis Ramudo-Cela +5 more
doaj +1 more source
Is CYP2D6 phenotype predictable from CYP2D6 genotype? [PDF]
Microchemical Journal, 2018 Abstract Genetic polymorphism of cytochrome P450s results in clinically significant modifications in patients' drug metabolizing capacities. CYP2D6 has a crucial role in the elimination of several clinically important drugs (antiarrhythmics, beta-adrenergic blockers, psychopharmacons and analgesics); however, the prediction of the phenotypic ...
Ádám Ferenc Kiss +6 more
openaire +2 more sources
Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan [PDF]
Clinical Pharmacology & Therapeutics, 2010 The pharmacokinetics of dextromethorphan (DM) is markedly influenced by cytochrome P450 2D6 (CYP2D6) enzyme polymorphisms. The aim of this study was to quantify the effects of the CYP2D6*1, *2, and *41 variants on DM metabolism in vivo and to identify other sources of pharmacokinetic variability.
Abduljalil, K +8 more
openaire +3 more sources